Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

SELLAS Life Sciences Group Inc. (SLS)

NASDAQ: SLS · Pharmaceutical Preparations · New York, NY

Our rating: Cautious

Cautious reaffirmed at $14.86, moderate conviction, November 19, 2026.

Breaks if: The Cautious call is wrong if SELLAS announces a successful pivotal-trial readout for its lead pipeline asset and either files for FDA approval or closes a licensing partnership that generates at least $30M in contractually committed forward revenue within the next 12 months — either of which would bridge the current zero-revenue reality to a commercially credible franchise. A sustained close above $22 (roughly 50% above today's price) driven by confirmed clinical or regulatory news would signal the market has priced a catalyst this analysis underweighted.

Key figures

Market value$2.8B
Revenue, last 12 monthsn/a
Net income, last 12 months−$36M
Free cash flow, last 12 monthsn/a
Price to earningsn/a
Free cash flow yieldn/a
Dividend yield0.0%
Operating marginn/a
Return on equity−40.3%
Beta to the S&P 5000.87
Volatility, annualized136.1%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$0.00n/a$-0.05n/a
June 30, 2026n/an/a$-0.05n/a
March 31, 2026n/an/a$-0.05n/a
December 31, 2025n/an/a$-0.05n/a
September 30, 2025$0.00n/a$-0.06n/a
June 30, 2025n/an/a$-0.07n/a
March 31, 2025n/an/a$-0.07n/a
December 31, 2024n/an/a$-0.08n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

34 ledger entries and 140 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.